We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Circulating Tumor Cell Dynamics Predicts Cancer Prognosis

By LabMedica International staff writers
Posted on 23 Dec 2020
Print article
Image: The CELLSEARCH Circulating Tumor Cell (CTC) Test is used for determining the prognosis of patients with metastatic breast, prostate and colorectal cancer (Photo courtesy of Menarini Silicon Biosystems).
Image: The CELLSEARCH Circulating Tumor Cell (CTC) Test is used for determining the prognosis of patients with metastatic breast, prostate and colorectal cancer (Photo courtesy of Menarini Silicon Biosystems).
Metastatic breast cancer, also called stage IV breast cancer, means the cancer has traveled through the bloodstream to create tumors in the liver, lungs, brain, bones and/or other parts of the body. Approximately 20% to 30% of women with early stage breast cancer go on to develop metastatic disease.

Circulating tumor cells (CTCs), are tumor cells that diffuse into the circulating blood and serve an important role in the progress of cancer. During the early stages of cancer, CTCs undergo an epithelial‑mesenchymal transition and obtain a more invasive phenotype. The development of robust and clinical study-friendly techniques has led to thorough investigation of CTCs as biomarkers in stage IV breast cancer, where CTCs can frequently be detected.

Scientists at the Ulm University Hospital (Ulm, Germany) investigated the potential of CTCs, which are shed from the primary tumor into the bloodstream, to predict overall survival. They analyzed global pooled datasets from peer-reviewed and published studies of 4,079 patients with metastatic breast cancer, all of whom had undergone baseline and follow-up CTC measurements using the CellSearch test (Menarini Silicon Biosystems Inc, Huntington Valley, PA, USA). The median time from baseline to follow-up was 29 days. Changes in CTC levels between baseline and follow-up were analyzed to determine whether they were associated with overall survival.

The investigators reported that of the 2,961 patients who were CTC-positive at baseline, 1,855 remained CTC-positive after initiating treatment (positive/positive), and 1,106 patients had converted to CTC-negative (positive/negative). Of the 1,118 patients who were CTC-negative at baseline, 813 remained CTC-negative (negative/negative), while 305 had become CTC-positive (negative/positive). Median overall survival was greatest for patients who were negative/negative (47 months), followed by positive/negative (32.2 months), negative/positive (29.7 months), and positive/positive (17.9 months).

Compared to patients who were negative/negative, the risk of death was 215% greater for those who were positive/positive, 74% greater for negative/positive, and 52% greater for positive/negative. For patients who were CTC-positive at baseline, those who remained CTC-positive at follow-up had a 51% greater risk of death than those who converted to CTC-negative. Similar trends were found when CTC dynamics were analyzed by breast cancer subtype, including for hormone receptor-positive, HER2-positive, and triple-negative breast cancers. CTC dynamics were associated with overall survival for all breast cancer subtypes.

Wolfgang Janni, MD, PhD, a professor of Obstetrics and Gynecology and a senior author of the study, said, “With the increasing number of treatment options available to patients with metastatic breast cancer, being able to predict and monitor treatment responses rapidly will be critical to aiding treatment decisions. We were interested in determining whether treatment response and prognosis could be predicted earlier using a simple blood test.” The study was presented at the virtual 2020 San Antonio Breast Cancer Symposium, held December 8-11.




New
Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
New
SARS-CoV-2 PCR Assay
AppliedBiosystems TaqCheck SARS-CoV-2 Fast PCR Assay Kit
New
SARS-CoV-2 RUO Solution
QuantiFERON SARS-CoV-2 RUO
COVID-19 Anitibody Test
TGS COVID-19 IgG

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis (Photo courtesy of Dr. Christopher Wiley)

Novel Lipid Biomarker Detects Senescent Cells

A recent paper identified a lipid biomarker indicative of cellular senescence and described a method to evaluate its effect on the molecular events that lead to senescence. Cellular senescence is a... Read more

Industry

view channel
Image: The Luminex Aries® System (Photo courtesy of Luminex Corporation)

DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space

DiaSorin S.p.A. (‎Saluggia‎, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.